AstraZeneca PLC Wins EU Approval for Heart Drug, Brillinta also Known as Brillique, to Rival Pfizer Inc.'s Plavix

September 24, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON, Sept 24 (Reuters) - AstraZeneca’s (AZN.L) new heart medicine Brilinta won a green light from regulators on Europe on Friday, boosting prospects for the group’s biggest drug hope.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Europe

AstraZeneca Pharmaceuticals LP Pfizer